• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Rockwell Medical Inc.

    8/14/25 4:11:24 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    S-8 1 tm2522781d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on August 14, 2025

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ROCKWELL MEDICAL, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   38-3317208
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

    30142 S. Wixom Road
    Wixom, Michigan 48393

    (248) 960-9009

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan

     

    (Full title of the plans)

     

     

    Mark Strobeck, Ph.D.

    President and Chief Executive Officer

    Rockwell Medical, Inc.

    30142 S. Wixom Road

    Wixom, Michigan 48393

    (248) 960-9009

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Ryan A. Murr
    Gibson, Dunn & Crutcher LLP
    One Embarcadero Center, Suite 2600
    San Francisco, CA 94111
    (415) 393-8200
    ​ Megan C. Timmins
    EVP, Chief Legal Officer and Secretary
    Rockwell Medical, Inc.
    30142 S. Wixom Road
    Wixom, Michigan 48393
    (248) 960-9009

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a small reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
           
    Non-accelerated filer x   Smaller reporting company x
           
          Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed to register an additional 5,000,000 shares of Rockwell Medical, Inc. (the “Company” or the “Registrant”) common stock, par value $0.0001, issuable under the Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan. The information contained in the Registrant’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on September 14, 2018 (File No. 333-227365), June 2, 2020 (File No. 333-238889), August 16, 2022 (File No. 333-266892), and August 15, 2023 (File No. 333-273985), together with all exhibits filed therewith or incorporated therein by reference, is hereby incorporated by reference pursuant to General Instruction E to Form S-8.

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
       
    4.1   Certificate of Incorporation, effective as of August 30, 2019 (incorporated by reference to Exhibit 3.3 to the Company’s Form 8-K filed August 30, 2019).
         
    4.2   Certificate of Amendment to Certificate of Incorporation of Rockwell Medical, Inc., dated May 12, 2022 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed May 13, 2022).
         
    4.3   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company's Form 10-Q filed November 14, 2022).
         
    5.1*   Opinion of Gibson, Dunn & Crutcher LLP.
       
    23.1*   Consent of Independent Registered Public Accounting Firm.
         
    23.2*   Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1).
       
    24.1*   Power of Attorney (included in signature page to this Registration Statement)
         
    99.1   Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q filed August 14, 2025).
         
    107.1*   Calculation of Filing Fee Table.

     

     

    *Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wixom, State of Michigan, on this 14th day of August, 2025.

     

      ROCKWELL MEDICAL, INC.
         
      By: /s/ Mark Strobeck
        Name: Mark Strobeck, Ph.D.
        Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Strobeck, Ph.D. and Megan Timmins, and each of them acting individually, as his or her attorney-in-fact, with full power of substitution, for him or her and in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including any post-effective amendments thereto) and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Name and Signature   Title   Date
             
    /s/ Mark Strobeck   President, Chief Executive Officer and Director   August 14, 2025
    Mark Strobeck, Ph.D.   (Principal Executive Officer)    
             
    /s/ Jesse Neri   Senior Vice President, Chief Financial Officer   August 14, 2025
    Jesse Neri   (Principal Financial Officer)    
             
    /s/ Nicholas Fanslau   Controller   August 14, 2025
    Nicholas Fanslau   (Principal Accounting Officer)    
             
    /s/ Robert S. Radie   Director and Chairman of the Board   August 14, 2025
    Robert S. Radie        
             
    /s/ John G. Cooper   Director   August 14, 2025
    John G. Cooper        
             
    /s/ Joan Lau   Director   August 14, 2025
    Joan Lau, Ph.D.        
             
    /s/ Allen Nissenson   Director   August 14, 2025
    Allen Nissenson, M.D.        
             
    /s/ Mark H. Ravich   Director   August 14, 2025
    Mark H. Ravich        
             
    /s/ Andrea Heslin Smiley   Director   August 14, 2025
    Andrea Heslin Smiley      

     

     

     

    Get the next $RMTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SVP and CCO Chole Timothy sold $2,352 worth of shares (2,868 units at $0.82), decreasing direct ownership by 2% to 128,167 units (SEC Form 4)

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    7/3/25 1:28:08 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President and CEO Strobeck Mark sold $5,679 worth of shares (6,926 units at $0.82), decreasing direct ownership by 2% to 337,752 units (SEC Form 4)

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    7/3/25 1:26:18 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SVP and CFO Neri Jesse sold $727 worth of shares (886 units at $0.82), decreasing direct ownership by 0.69% to 126,614 units (SEC Form 4)

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    7/3/25 1:24:06 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    SEC Filings

    View All

    SEC Form S-8 filed by Rockwell Medical Inc.

    S-8 - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    8/14/25 4:11:24 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Rockwell Medical Inc.

    10-Q - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    8/14/25 7:05:59 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    8/14/25 6:05:24 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Rockwell Medical with a new price target

    Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00

    11/14/24 7:56:29 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously

    1/18/22 10:00:06 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously

    9/7/21 6:17:47 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

    4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    4/15/25 2:02:44 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Financials

    Live finance-specific insights

    View All

    Rockwell Medical Announces Second Quarter 2025 Results

    Generated $1.8 million in cash flow from operations for the second quarter of 2025. Reported gross margin of 16% for the second quarter of 2025, in line with 2025 guidance. Increased cash position at June 30, 2025 to $18.4 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2025. "During the second quarter of 2025, we successfully managed through the transition of our largest customer away from Rockwell Medical and now find ou

    8/14/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical to Release Second Quarter 2025 Results on Thursday, August 14, 2025

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 14, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Resu

    7/17/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Announces First Quarter 2025 Results

    Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

    5/12/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rockwell Medical Announces Second Quarter 2025 Results

    Generated $1.8 million in cash flow from operations for the second quarter of 2025. Reported gross margin of 16% for the second quarter of 2025, in line with 2025 guidance. Increased cash position at June 30, 2025 to $18.4 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2025. "During the second quarter of 2025, we successfully managed through the transition of our largest customer away from Rockwell Medical and now find ou

    8/14/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical to Release Second Quarter 2025 Results on Thursday, August 14, 2025

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Thursday, August 14, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Resu

    7/17/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical and Innovative Renal Care Announce Three-Year Partnership Agreement to Ensure Supply Chain Continuity of Quality Hemodialysis Products

    Rockwell Medical, Inc. (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, and Innovative Renal Care (IRC), one of the largest dialysis service providers in the United States, today announced they signed a multi-year service agreement to support IRC's goals to invest in high-quality hemodialysis products, streamline workflows, and help avoid potential supply chain disruptions. Under the terms of the agreement, Rockwell Medical will supply IRC with liquid and dry, acid and bicarbonate hemodialysis concentrates, as well as the DAMX45 dry acid concentrate mix system, which is 51

    7/8/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Leadership Updates

    Live Leadership Updates

    View All

    Universal Display Corporation Announces the Appointment of New Board Members

    Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

    3/7/24 4:05:00 PM ET
    $BDN
    $NOTV
    $OLED
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

    Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

    10/17/23 6:00:00 AM ET
    $BDN
    $RMTI
    $RCOR
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

    WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci

    6/24/22 8:56:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    11/14/24 5:17:40 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Rockwell Medical Inc. (Amendment)

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    2/14/24 2:31:02 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Rockwell Medical Inc. (Amendment)

    SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    9/6/23 4:49:44 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care